hTR-siRNA腺病毒对裸鼠人宫颈癌移植瘤的治疗作用

im To study the effect of the hTR-siRNA adenovirus on anti-tumor in vivo and its mechanism. Methods HeLa cells were subcutaneous inoculated into the right armpit of BALB/c nu/nu mice to establish the model of human cervical cancer. After successful implantation, the mice were randomized into four groups. The mice were intratumorally injected with 0.1ml of serum-free DMEM alone, or Ad-hTR-siRNA (1010 pfu/ml), or Ad-NT-siRNA (1010 pfu/ml), or cisplatin(1.20 mg/ml) as positive control. These different treatments were given once every 3 days for 15 consecutive days. After the last injection, mice were observed for 7 days continuously and sacrificed at the end. Tumors were excised, weighed, sectioned and assessed for morphology by HE and for apoptosis by the TUNEL assay. Results Tumors-implanted were established successfully by 100% with HeLa cells. As compared with Ad-NT-siRNA-treated mice, Ad-hTR-siRNA could slow down tumor growth, decrease tumor volume (45.48%) and tumor weight (34.68%) and push forward the apoptosis and necrosis of tumor cells. The TUNEL positive cells were about 11.8%. But the anti-tumor activity of Ad-hTR-siRNA didn’t catch on cisplatin’s. Conclusion It is supposed that the hTR-siRNA adenovirus could suppress cervical cancer-xenografted growth in vivo and induce tumor cell apoptosis or necrosis. All of these indicated the prospect of applying this siRNA expressing recombinant adenovirus system in cancer gene therapy.